141 related articles for article (PubMed ID: 36123781)
41. mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1).
Kamalinia G; Engel BJ; Srinivasamani A; Grindel BJ; Ong JN; Curran MA; Takahashi TT; Millward SW; Roberts RW
ACS Chem Biol; 2020 Jun; 15(6):1630-1641. PubMed ID: 32352272
[TBL] [Abstract][Full Text] [Related]
42. MicroRNA-140 suppresses osteosarcoma tumor growth by enhancing anti-tumor immune response and blocking mTOR signaling.
Ji X; Wang E; Tian F
Biochem Biophys Res Commun; 2018 Jan; 495(1):1342-1348. PubMed ID: 29170130
[TBL] [Abstract][Full Text] [Related]
43. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
44. Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy.
Li L; Miao Q; Meng F; Li B; Xue T; Fang T; Zhang Z; Zhang J; Ye X; Kang Y; Zhang X; Chen Q; Liang X; Chen H; Zhang X
Theranostics; 2021; 11(12):6033-6043. PubMed ID: 33897897
[TBL] [Abstract][Full Text] [Related]
45. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.
Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A
Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337
[TBL] [Abstract][Full Text] [Related]
46. Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression.
Zheng NN; Zhou M; Sun F; Huai MX; Zhang Y; Qu CY; Shen F; Xu LM
World J Gastroenterol; 2020 Jul; 26(26):3737-3749. PubMed ID: 32774054
[TBL] [Abstract][Full Text] [Related]
47. A PD-L1 and VEGFR2 dual targeted peptide and its combination with irradiation for cancer immunotherapy.
Jiao L; Dong Q; Zhai W; Zhao W; Shi P; Wu Y; Zhou X; Gao Y
Pharmacol Res; 2022 Aug; 182():106343. PubMed ID: 35798286
[TBL] [Abstract][Full Text] [Related]
48. A novel form of immunotherapy using antigen peptides conjugated on PD-L1 antibody.
Lee EJ; Jang GY; Lee SE; Lee JW; Han HD; Park YM; Kang TH
Immunol Lett; 2021 Dec; 240():137-148. PubMed ID: 34710507
[TBL] [Abstract][Full Text] [Related]
49. Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression.
Jin X; Ding D; Yan Y; Li H; Wang B; Ma L; Ye Z; Ma T; Wu Q; Rodrigues DN; Kohli M; Jimenez R; Wang L; Goodrich DW; de Bono J; Dong H; Wu H; Zhu R; Huang H
Mol Cell; 2019 Jan; 73(1):22-35.e6. PubMed ID: 30527665
[TBL] [Abstract][Full Text] [Related]
50. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
51. Autophagy inhibitor enhance ZnPc/BSA nanoparticle induced photodynamic therapy by suppressing PD-L1 expression in osteosarcoma immunotherapy.
Yu W; Wang Y; Zhu J; Jin L; Liu B; Xia K; Wang J; Gao J; Liang C; Tao H
Biomaterials; 2019 Feb; 192():128-139. PubMed ID: 30448697
[TBL] [Abstract][Full Text] [Related]
52. Design, synthesis and biological evaluation of PD-1 derived peptides as inhibitors of PD-1/PD-L1 complex formation for cancer therapy.
Bojko M; Węgrzyn K; Sikorska E; Kocikowski M; Parys M; Battin C; Steinberger P; Kogut MM; Winnicki M; Sieradzan AK; Spodzieja M; Rodziewicz-Motowidło S
Bioorg Chem; 2022 Nov; 128():106047. PubMed ID: 35963023
[TBL] [Abstract][Full Text] [Related]
53. Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.
Liao Y; Chen L; Feng Y; Shen J; Gao Y; Cote G; Choy E; Harmon D; Mankin H; Hornicek F; Duan Z
Oncotarget; 2017 May; 8(18):30276-30287. PubMed ID: 28415820
[TBL] [Abstract][Full Text] [Related]
54. The role of exosomal PD-L1 in tumor progression and immunotherapy.
Xie F; Xu M; Lu J; Mao L; Wang S
Mol Cancer; 2019 Oct; 18(1):146. PubMed ID: 31647023
[TBL] [Abstract][Full Text] [Related]
55. Phage display-identified PD-L1-binding peptides reinvigorate T-cell activity and inhibit tumor progression.
Gurung S; Khan F; Gunassekaran GR; Yoo JD; Poongkavithai Vadevoo SM; Permpoon U; Kim SH; Kim HJ; Kim IS; Han H; Park JH; Kim S; Lee B
Biomaterials; 2020 Jul; 247():119984. PubMed ID: 32278214
[TBL] [Abstract][Full Text] [Related]
56. Engineered EGCG-Containing Biomimetic Nanoassemblies as Effective Delivery Platform for Enhanced Cancer Therapy.
Wu P; Zhang H; Yin Y; Sun M; Mao S; Chen H; Deng Y; Chen S; Li S; Sun B
Adv Sci (Weinh); 2022 May; 9(15):e2105894. PubMed ID: 35486032
[TBL] [Abstract][Full Text] [Related]
57. MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression.
Lin J; Xu A; Jin J; Zhang M; Lou J; Qian C; Zhu J; Wang Y; Yang Z; Li X; Yu W; Liu B; Tao H
Oncoimmunology; 2022; 11(1):2024941. PubMed ID: 35036076
[TBL] [Abstract][Full Text] [Related]
58. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
[TBL] [Abstract][Full Text] [Related]
59. A Novel Small Cyclic Peptide-Based
Liu H; Hu M; Deng J; Zhao Y; Peng D; Feng Y; Wang L; Chen Y; Qiu L
Mol Pharm; 2022 Jan; 19(1):138-147. PubMed ID: 34910492
[TBL] [Abstract][Full Text] [Related]
60. Engineered DBCO+PD-1 Nanovesicles Carrying 1-MT for Cancer-Targeted Immunotherapy.
Xu X; Liu L; Wang H; Li W; Zou Y; Zeng Y; Yang Q; Bai D; Dai D
ACS Biomater Sci Eng; 2022 Nov; 8(11):4819-4826. PubMed ID: 36206367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
